GlassScriptPhysician profile
Elaina Williams
NPI 1851734479
$4,200.24
in general payments reported to CMS, 2019-2025
24 companies · $630 in 2025
The $630 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $606 · 2021: $986 · 2022: $482 · 2023: $458 · 2024: $705 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $837.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $752.37 | 2019-2025 | |
| Novo Nordisk INC | $690.06 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $606.77 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $275.22 | 2021-2024 | |
| Glaxosmithkline, LLC. | $149.61 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $148.17 | 2019-2023 | Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.42 | 2021-2024 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $113.45 | 2020-2022 | |
| Amgen INC. | $90.38 | 2020-2021 | |
| Amarin Pharma, INC. | $65.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $49.51 | 2024-2025 | Eliquis |
| Exact Sciences Corporation | $45.15 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $36.01 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.43 | 2023-2025 | Xifaxan |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.73 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $30.31 | 2019-2020 | |
| Corcept Therapeutics | $24.50 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $20.87 | 2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $18.76 | 2024 | |
| Inspire Medical Systems, INC. | $15.08 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $13.93 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaina Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.